entertainment -WSS

entertainment

author：fashion 2025-09-14 10:08:54 - browse：754

Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion consumer health division, which is exploring over-the-counter moves for the erectile dysfunction drug Cialis and the flu treatment Tamiflu.

Investors reacted swiftly, bidding Sanofi’s American depository receipts on the New York Stock Exchange down nearly 18% to less than $44 in morning trading. Jared Holz, an analyst at Mizuho, warned investors that the drop “would be the largest negative single-day stock move across Global Pharma in more than ten years.”

It would be tempting to take the stock move as evidence that investors have finally tired of watching drug companies treat consumer product divisions like baseball trading cards, buying them at a high price only to sell them again a decade later. But the move probably has little to do with the current passion for pharma spinouts or with Sanofi following in the footsteps of GSK, Novartis, and Pfizer in shedding a division. Or even, for that matter, Sanofi, which shed its pharmaceutical ingredients business, EuroAPI, which is now trading at a third of its initial public offering price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Spinal cord stimulation reduces pain in amputees, study finds

WSS

3 trends to watch in health tech's hiring outlook for 2024

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

FDA approves world's first CRISPR

The FDA must approve intranasal treatments for anaphylaxis

Chemotherapy shortages won’t get better under Biden’s latest plan

Videos point to link between seizures and unexplained toddler deaths

focus

entertainment

explore

Virginia high school admissions case could be legal follow

STAT letters to the editor on burnt

After affirmative action ruling, medical educators look to 'holistic review'

Chemotherapy shortages won’t get better under Biden’s latest plan

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Teach medical students about patients with intellectual disabilities

Activists slam private health insurers over coverage restrictions

Roche to buy Carmot Therapeutics, developer of obesity drugs

United colonoscopy coverage change 'may cost lives,' doctors say

AI models in health care face new federal disclosure requirements

hotspot

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Antibiotic resistance and the global rise in human conflict

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Burning questions for the 2024 JPM Healthcare Conference

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

3 trends to watch in health tech's hiring outlook for 2024

explore

hotspot

focus

leisure time